Análisis coste-efectividad y coste-utilidad de apixaban frente a dabigatrán y rivaroxaban en el tratamiento y prevención secundaria del tromboembolismo venoso

Authors
Publication date
1 January 2017
Publisher
Springer Science and Business Media LLC
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1007%2Fs40277-016-...
      Last time updated on 28/03/2019

      Springer - Publisher Connector

      redirect
      Last time updated on 01/05/2017